Why has it been so difficult to prove the efficacy of alpha-1-antitrypsin replacement therapy? Insights from the study of disease pathogenesis.

Dickens, Jennifer A; Lomas, David A

Dickens, Jennifer A; Lomas, David A.

Affiliation

Dickens JA; Department of Medicine, University of Cambridge, Cambridge Institute for Medical Research, Wellcome Trust/MRC Building, Cambridge, UK.

Drug Des Devel Ther ; 5: 391-405, 2011.

Article in En | MEDLINE | ID: mdl-21966212

Subject(s)

Lung Diseases/drug therapy; alpha 1-Antitrypsin Deficiency/drug therapy; alpha 1-Antitrypsin/administration & dosage; Clinical Trials as Topic; Emphysema/drug therapy; Emphysema/physiopathology; Humans; Inflammation/drug therapy; Inflammation/physiopathology; Lung Diseases/physiopathology; Mutation; Treatment Outcome; alpha 1-Antitrypsin/blood; alpha 1-Antitrypsin Deficiency/genetics; alpha 1-Antitrypsin Deficiency/physiopathology

Key words

augmentation therapy; emphysema; α1-antitrypsin deficiency

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Alpha 1-Antitrypsin / Alpha 1-Antitrypsin Deficiency / Lung Diseases Type of study: Etiology_studies Limits: Humans Language: En Year: 2011 Type: Article

Fulltext

XML

PubMed Links

Search on Google